<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01686815</url>
  </required_header>
  <id_info>
    <org_study_id>CILO522DUSXXT</org_study_id>
    <nct_id>NCT01686815</nct_id>
  </id_info>
  <brief_title>Cross-Sectional Iloperidone IVGTT</brief_title>
  <official_title>Cross-sectional Study to Compare Glucose and Lipid Metabolism in SMI Subjects Treated With Either Fanapt (Iloperidone), Zyprexa (Olanzapine), or Risperdal (Risperidone)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to utilize state of the art procedures such as the frequently sampled&#xD;
      intravenous glucose tolerance test (FSIVGTT), Bergman's Minimal Model Analysis, lipoprotein&#xD;
      analysis, and DEXA scans to demonstrate that a newer agent, iloperidone, is devoid of the&#xD;
      metabolic abnormalities associated with other atypical antipsychotic treatments, namely&#xD;
      olanzapine and risperidone, and offers an advantage over these other agents.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This one-month research study examines how Fanapt® (iloperidone), Zyprexa® (olanzapine), or&#xD;
      Risperdal® (risperidone) affect glucose metabolism in patients with schizophrenia,&#xD;
      schizoaffective disorder, bipolar disorder, major depressive disorder, psychosis NOS,&#xD;
      delusional disorder or paranoid disorder. This study requires 3 research visits and includes&#xD;
      a physical exam, medical history, vitals, an EKG, cognitive testing, psychological rating&#xD;
      scales, a DEXA scan, a nutritional assessment, a 3-hour intravenous glucose tolerance test&#xD;
      (IVGTT) and a fasting blood draw.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Actual">May 2016</completion_date>
  <primary_completion_date type="Actual">May 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Difference between cohorts in glucose metabolism</measure>
    <time_frame>Baseline</time_frame>
    <description>Difference between olanzapine- or risperidone-treated subjects, and Iloperidone-treated subjects on glucose metabolism as measured by the FSIVGTT procedure at one time point (Baseline).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Difference between cohorts in triglycerides</measure>
    <time_frame>Baseline</time_frame>
    <description>Difference between olanzapine- or risperidone-subjects and subjects treated with iloperidone in triglyceride levels measured at one time point (Baseline).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Difference between cohorts on LDL cholesterol</measure>
    <time_frame>Baseline</time_frame>
    <description>Difference between olanzapine- or risperidone-subjects and subjects treated with iloperidone in LDL cholesterol levels measured at one time point (Baseline).</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">37</enrollment>
  <condition>Schizophrenia</condition>
  <condition>Serious Mental Illness</condition>
  <condition>Metabolic Syndrome</condition>
  <condition>Insulin Resistance</condition>
  <condition>Glucose Metabolism</condition>
  <arm_group>
    <arm_group_label>Olanzapine</arm_group_label>
    <description>Olanzapine-treated patients with serious mental illness, such as schizophrenia, schizoaffective disorder, bipolar disorder, major depressive disorder, psychosis NOS, delusional disorder or paranoid disorder.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Risperidone</arm_group_label>
    <description>Risperidone-treated patients with serious mental illness, such as schizophrenia, schizoaffective disorder, bipolar disorder, major depressive disorder, psychosis NOS, delusional disorder or paranoid disorder.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Iloperidone</arm_group_label>
    <description>Iloperidone-treated patients with serious mental illness, such as schizophrenia, schizoaffective disorder, bipolar disorder, major depressive disorder, psychosis NOS, delusional disorder or paranoid disorder.</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Samples will be retained to test IL-6 and other inflammatory markers.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects will include 60 outpatients between the ages of 18-65 with schizophrenia,&#xD;
        schizoaffective disorder, bipolar disorder, major depressive disorder, psychosis NOS,&#xD;
        delusional disorder or paranoid disorder. 60 subjects will be screened and 45 will enter&#xD;
        the cross-sectional study (15 olanzapine, 15 iloperidone, 15 risperidone-treated subjects&#xD;
        matched for BMI).&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male/Female ages 18-65 years&#xD;
&#xD;
          2. Capacity to provide informed consent&#xD;
&#xD;
          3. BMI between 20 and 30 kg/m²&#xD;
&#xD;
          4. Diagnosis of a serious mental illness, including schizophrenia, any subtype;&#xD;
             schizoaffective disorder, any subtype; major depressive disorder, bipolar disorder,&#xD;
             psychosis NOS, delusional disorder and paranoid disorder&#xD;
&#xD;
          5. Treatment with iloperidone, risperidone, or olanzapine for at least 6 months&#xD;
&#xD;
          6. Stable dose of antipsychotic agent for at least one month&#xD;
&#xD;
          7. Well established compliance with out-patient medications and clinically stable&#xD;
&#xD;
          8. Female subjects will be eligible to participate in the study if they are of&#xD;
             non-childbearing potential or of child-bearing potential and willing to practice&#xD;
             appropriate birth control methods (complete abstinence from sexual intercourse, female&#xD;
             sterilization, sterilization of male partner, implants of levonorgestrel, injectable&#xD;
             progestogen, oral contraceptives, intrauterine devices, or double barrier methods of&#xD;
             contraception using spermicide with either a condom or diaphragm) during the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Inability to provide informed consent&#xD;
&#xD;
          2. Current substance abuse&#xD;
&#xD;
          3. Psychiatrically unstable and/or hospitalized in the past month&#xD;
&#xD;
          4. History of significant and untreated medical illness including severe cardiovascular,&#xD;
             hepatic, renal, or untreated thyroid disease; hepatitis; or HIV&#xD;
&#xD;
          5. Current insulin treatment for diabetes&#xD;
&#xD;
          6. Currently taking the following medications: birth control pills containing norgestrol,&#xD;
             steroids, thiazide diuretics, or treatment with agents that induce weight loss&#xD;
&#xD;
          7. Intentions of donating blood during or within 30 days of completion of the study.&#xD;
&#xD;
          8. Use of valproate or carbamazepine within four weeks of the study&#xD;
&#xD;
          9. History of immunosuppression&#xD;
&#xD;
         10. Current or recent radiation or chemotherapy treatment for cancer&#xD;
&#xD;
         11. Pregnancy or breastfeeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maurizio Fava, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>September 13, 2012</study_first_submitted>
  <study_first_submitted_qc>September 13, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 18, 2012</study_first_posted>
  <last_update_submitted>March 8, 2019</last_update_submitted>
  <last_update_submitted_qc>March 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Maurizio Fava, MD</investigator_full_name>
    <investigator_title>Vice Chair, Psychiatry</investigator_title>
  </responsible_party>
  <keyword>metabolic side effects</keyword>
  <keyword>atypical antipsychotics</keyword>
  <keyword>FSIVGTT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metabolic Syndrome</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>Mental Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

